MARC Record from Library of Congress

LEADER: 02142cam a2200385 a 4500
001 2007013738
003 DLC
005 20080215165757.0
008 070403s2007 njua b 001 0 eng
010 $a 2007013738
020 $a9789812705761 (hardcover)
020 $a9812705767 (hardcover)
020 $a9789812707789 (pbk.)
020 $a9812707786 (pbk.)
035 $a(DNLM)101303623
040 $aDNLM/DLC$cDLC$dDLC
050 00 $aRM171.7$b.C478 2007
060 10 $aWH 450$bC456a 2007
082 00 $a615/.39$222
100 1 $aChang, Thomas Ming Swi.
245 10 $aArtificial cells :$bbiotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation, cell/stem cell therapy /$cThomas Ming Swi Chang.
260 $aHackensack, N. J. :$bWorld Scientific,$cc2007.
300 $axxvi, 455 p. :$bill. (some col.) ;$c24 cm.
440 0 $aRegenerative medicine, artificial cells and nanomedicine ;$vv. 1
504 $aIncludes bibliographical references (p. 377-440) and index.
505 0 $a50th anniversary of artificial cells -- Basic principles -- Oxygen carriers based on nanobiotechnology -- A nanobiotechnologic therapeutic that transports oxygen and remove oxygen radicals: for stroke, hemorrhagic shock and related conditions -- Nanotechnology-based artificial red blood cells (RBC's) -- Use of enzyme artificial cells for genetic enzyme defects that increase systemic substrates to toxic levels -- Enzyme artificial cells in substrate-dependent tumors and activation of prodrug -- Artificial cells for cell encapsulation -- Artificial cells containing hepatocytes and/or stem cells in regenerative medicine -- Hemoperfusion in poisoning, kidney failure, liver failure, and immunology -- Perspectives on the future of artificial cells as suggested by past research.
650 0 $aArtificial cells.
650 0 $aBlood substitutes.
650 0 $aNanotechnology.
650 12 $aBlood Substitutes.
650 22 $aBiotechnology.
650 22 $aCells.
650 22 $aNanomedicine.
650 22 $aRegenerative Medicine.
856 41 $3Table of contents only$uhttp://www.loc.gov/catdir/toc/ecip0715/2007013738.html